Company Dossier · Health Care
BrightSpring Health Services
- MidCap 400
What BrightSpring Health Services is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.
Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →
The latest read
Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.
- Revenue over the four quarters to June 30, 2026: $14.4 billion, up 26% from a year earlier.SEC EDGAR filings (XBRL)
- Free cash flow (operating cash flow minus capital expenditure) over the four quarters to June 30, 2026: $0.40 billion, up 111% from a year earlier.SEC EDGAR filings (XBRL)
- Capital expenditure over the four quarters to June 30, 2026: $0.10 billion, up 25% from a year earlier.SEC EDGAR filings (XBRL)
- Share buybacks in the fiscal year to December 31, 2025: $0.04 billion.SEC EDGAR filings (10-K)
- Long-term debt issued in the fiscal year to December 31, 2024: $2.57 billion.SEC EDGAR filings (10-K)
- Latest earnings call or results release (July 31, 2026): sentiment 0.70 on a −1 to +1 scale (confident, opportunity-framed), confidence 0.80 of 1.Palanor Discourse
- Guidance in the last 90 days: 4 outlook figures raised, 0 lowered, 0 held.Guidance Ledger (8-K results releases)
- Latest annual report (filed February 27, 2026): 0 risk factors added, 1 removed.Risk Factor Changes (10-K Item 1A)
- Insiders were net sellers in Q3 2026: $0.9 million on the open market.SEC Form 4
- 422 institutional managers reported a position at June 30, 2026 (+84 on the quarter before).SEC Form 13F
- H-1B filings certified in Q2 2026: 2 (0 a year earlier).U.S. Department of Labor (OFLC)
Company Posture
How Company Posture is measured →Company Posture covers S&P 500 companies.
Credit
How these are built →No bond term sheets or tagged debt on file for BrightSpring Health Services yet.
Charts
Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.
Cash flow
Capital returned and raised
What the company says
Hiring and ownership
In the news
Headlines that name BrightSpring Health Services, with the publisher and a link. The tone is read from each headline’s own words, never from a summary of the article.
- NeutralBrightSpring Health Services Inc (BTSG) Stock Up 5.2% but GF Value Says Overvalued -- GF Score: 44/100
gurufocus.com · via Marketaux · Oct 2, 2026
Filings and records
The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.
- Oct 20, 2026LobbyingLobbying report (FEDERAL HEALTH POLICY STRATEGIES)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (AKIN GUMP STRAUSS HAUER & FELD)third_quarter 2026 · $0.0 million
- Jul 20, 2026LobbyingLobbying report (FEDERAL HEALTH POLICY STRATEGIES)second_quarter 2026 · $0.1 million
- Jul 20, 2026LobbyingLobbying report (AKIN GUMP STRAUSS HAUER & FELD)second_quarter 2026 · $0.0 million
- Jun 12, 20268-KDirector or officer changeItem 5.02
- Jun 5, 20268-KMaterial agreement signedItem 1.01
- May 21, 20268-KShareholder vote resultsItem 5.07
- Apr 20, 2026LobbyingLobbying report (AKIN GUMP STRAUSS HAUER & FELD)first_quarter 2026 · $0.0 million
- Apr 20, 2026LobbyingLobbying report (FEDERAL HEALTH POLICY STRATEGIES)first_quarter 2026 · $0.1 million
- Apr 17, 2026LobbyingLobbying report (BRIGHTSPRING HEALTH SERVICES)first_quarter 2026 · $0.2 million
- Apr 17, 2026LobbyingLobbying report (BRIGHTSPRING HEALTH SERVICES)first_quarter 2026 · $0.2 million
- Mar 31, 20268-KAcquisition or sale completedItem 2.01
- Mar 31, 20268-KDirector or officer changeItem 5.02
- Mar 4, 20268-KMaterial agreement signedItem 1.01
- Feb 27, 202610-KAnnual report (10-K)0 risk factors added, 1 removed
- Oct 22, 20258-KMaterial agreement signedItem 1.01
- Jun 20, 20258-KDirector or officer changeItem 5.02
- Jun 12, 20258-KMaterial agreement signedItem 1.01
- Jun 3, 20258-KShareholder vote resultsItem 5.07
- Apr 15, 20258-KDirector or officer changeItem 5.02
- Mar 6, 202510-KAnnual report (10-K)1 risk factors added, 4 removed
- Mar 5, 20258-KDirector or officer changeItem 5.02
- Jan 21, 20258-KMaterial agreement signedItem 1.01
- Dec 11, 20248-KMaterial agreement signedItem 1.01
- Nov 15, 20248-KDirector or officer changeItem 5.02
- Mar 6, 202410-K
Peers
Companies in the same sector in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.
| Company | Revenue | Free cash flow | Through |
|---|---|---|---|
| Labcorp LH | $14.3B | $1.2B | Jun 30, 2026 |
| Viatris VTRS | $14.7B | $1.9B | Jun 30, 2026 |
| DaVita DVA | $14.0B | $1.6B | Jun 30, 2026 |
| Henry Schein HSIC | $13.6B | $0.6B | Jun 27, 2026 |
| Regeneron Pharmaceuticals REGN | $15.5B | $3.8B | Jun 30, 2026 |
| Vertex Pharmaceuticals VRTX | $12.6B | $3.8B | Jun 30, 2026 |
| IQVIA IQV | $16.6B | $2.1B | Mar 31, 2026 |
| Quest Diagnostics DGX | $11.6B | $1.4B | Jun 30, 2026 |
Identity
- SEC CIK
- 1865782